Topic: Gilead

The FDA has approved Lenacapavir, a twice-yearly injection that is reportedly over 99.9% effective at preventing HIV. Manufacturer Gilead Sciences set the list price at approximately $28,000 per year. While medical professionals hail it as a breakthrough for those who struggle with daily pill compliance, critics question the high cost and the reliance on federal funding for access.

The FBI and federal cybersecurity agents warned that hackers linked to the Chinese and Iranian governments were targeting U.S. universities and pharmaceutical companies to steal COVID-19 research. Assistant Attorney General John Demers stated that China is desperate to be the first to develop a vaccine for geopolitical prestige. Tensions escalated as President Trump suggested reporters "ask China" about the global death toll during a press briefing.

Adam Curry reacts to Michelle Obama's DNC claim that she used IVF to become a mother, questioning why this information is only surfacing now. The hosts discuss the frequent comparisons between Project 2025 and Margaret Atwood's "The Handmaid's Tale," with Dvorak reading the book's plot to demonstrate the lack of actual parallels.

Investigative reporter Sharyl Attkisson released a report detailing the financial interests behind the transgender advocacy movement, identifying pharmaceutical companies as primary funders. The report highlights that Gilead Sciences, a major producer of HIV medications, and AbbVie, the manufacturer of the puberty-suppressing drug Lupron, are top donors to trans organizations. Critics argue this creates a "Transgender Leviathan" where medical profits drive social policy and pediatric healthcare decisions.

Dr. Bryan Ardis testified that Anthony Fauci knowingly promoted Remdesivir despite its high mortality rate in African Ebola trials. Ardis claims the drug causes multiple organ failure, which is often misattributed to COVID-19. He expressed concern that the drug is now being authorized for use in children.

Discussions continue regarding the possibility of a lab leak in China, potentially through the sale of experimental animals. In the US, HHS Secretary Alex Azar defended containment measures while acknowledging the virus could not be hermetically sealed off. Meanwhile, European health ministers decided against closing internal borders, calling such measures inefficient for stopping the spread.

States like Florida and Texas began phased reopening plans for beaches and retail stores with occupancy limits. Gilead's stock rose following positive reports on Remdesivir's effectiveness in Chicago trials. Additionally, health officials confirmed the first US cases of pet cats testing positive for coronavirus in New York, though there was no evidence of animal-to-human transmission.

French doctor Didier Raoult, an early proponent of hydroxychloroquine, has alleged receiving death threats from individuals linked to Gilead Sciences. The conflict centers on the competition between the inexpensive hydroxychloroquine treatment and Gilead's high-priced Remdesivir. The hosts discuss the cutthroat nature of the pharmaceutical industry during the pandemic.

Dr. Simone Gold explained that the FDA cannot grant Emergency Use Authorization (EUA) for new vaccines if an existing, approved medication is effective against the target disease. She alleged that the suppression of hydroxychloroquine serves the financial interests of companies like Gilead, which produces the more expensive Remdesivir. This regulatory hurdle provides a potential motive for the intense public campaign against generic therapeutics.

Dr. Simone Gold and Dr. Stella Emanuel led a "Frontline Doctors" summit in Washington D.C. to protest the politicization of hydroxychloroquine. Emanuel delivered a passionate speech accusing the medical establishment, including Anthony Fauci and the WHO, of being complicit in unnecessary deaths by restricting access to the drug. The group called for a mass movement of doctors to defy hospital protocols and prioritize patient lives over pharmaceutical profits.

The United States has purchased virtually the entire global supply of Remdesivir for the next three months, totaling over 500,000 doses. The drug, which costs approximately $3,120 per patient, has replaced hydroxychloroquine as the preferred therapeutic in the public eye. The move is criticized as a "scam" driven by pharmaceutical interests rather than public health.

Clinical trials for Remdesivir showed a statistically significant but modest 32% reduction in recovery time for hospitalized COVID-19 patients. Dr. Fauci expressed optimism that drug combinations might provide an effective treatment bridge before a vaccine is widely available.

The discussion contrasts the low-cost combination of hydroxychloroquine and zinc with Gilead's expensive drug, Remdesivir. While Remdesivir was shown to shorten hospital stays by five days, it did not significantly reduce mortality rates. Critics argue that hydroxychloroquine is being suppressed because it is an "open source" drug with no profit potential for major pharmaceutical companies.

The FBI and federal cybersecurity agents issued a warning that hackers linked to the Chinese government are attempting to steal U.S. research on COVID-19 vaccines and treatments. Iran is also accused of targeting executives at Gilead Sciences, the maker of Remdesivir. The hosts also comment on the vocal condition of CBS correspondent Jeff Pegues during his reporting.

The FDA has fast-tracked Remdesivir, a drug by Gilead, while hydroxychloroquine continues to face media skepticism despite its use in India and Africa. Robert F. Kennedy Jr. also claimed that the CDC inflates annual flu death statistics by counting general pneumonia deaths to drive vaccine sales. He suggests that the actual number of influenza deaths is closer to 1,000 per year rather than the 60,000 often cited.

During an Oval Office announcement, Gilead's CEO discussed the donation of 1.5 million vials of Remdesivir to the U.S. government for hospitalized patients. A controversy emerged when the Associated Press allegedly edited the video clip to add phony applause and a "fantastic" comment from President Trump that did not occur in the original broadcast. This incident is cited as an example of media outlets fabricating narratives to suit their reporting.

Dr. Anthony Fauci announced positive results from an NIAID trial of Gilead’s Remdesivir, noting a 31% improvement in recovery time for COVID-19 patients. The study showed recovery times dropping from 15 days to 11 days, which Fauci compared to the breakthrough of HIV drugs in the 1980s. The drug is expected to receive emergency use authorization from the FDA as a new standard of care.

Prior to the recent NIH success, Remdesivir faced negative press following a leaked video from the University of Chicago and reports on the health news site STAT. Initial interpretations of the data were considered disappointing, causing Gilead's stock to sink. Critics point out that the recovery time improvement now being celebrated was previously dismissed as statistically insignificant "office chatter."

The rapid promotion of Remdesivir mirrors the historical rollout of HIV treatments like Truvada, which was also developed by Gilead Sciences. Dr. Anthony Fauci and Dr. Deborah Birx have long-standing ties to Gilead through their decades of work on the HIV mission at the NIH. The current push for Remdesivir is seen by some as a pharmaceutical-heavy approach that favors hospital-administered IV treatments over cheaper, oral alternatives.

A CNBC report on a VA hospital study suggested hydroxychloroquine increased death rates, but the study's lack of peer review and control groups is criticized. Dr. Drew Pinsky is cited regarding the drug's safety profile and its routine use by physicians despite media skepticism.